Merck & Co. and Moderna have shared highly anticipated phase 3 data on their cancer vaccine, revealing a primary endpoint hit ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
Celltrion has licensed a preclinical antibody aimed at autoimmune conditions from Maryland-based biotech Kaigene in a deal ...
AbbVie’s next-generation Crohn’s disease combination candidate has beaten Skyrizi in a midphase clinical trial. Skyrizi is a ...
Nouscom has reeled in 120 million euros ($135 million) in series D funds to take a cancer-preventing vaccine through a ...
‘A two-way conversation with the tumor’: Researchers use ‘avatar’ to predict immunotherapy responses
Researchers are exploring a revolutionary way to predict a patient's response to immunotherapies by creating a tumor “avatar” ...
Reverse mergers have returned with a bang. More biotechs have taken this back door to the public markets so far in 2026 than ...
Lycia Therapeutics is banking on a $227.8 million IPO as the biotech seeks to finance its pipeline of protein degraders for ...
Rapport's phase 2 bipolar win strikes chord with analysts despite falling short of original ambition
Rapport Therapeutics’ phase 2 bipolar mania study has hit its primary endpoint, furthering the biotech’s efforts to make RAP-219 a multi-indication blockbuster. However, the effect size fell short of ...
Enlivex is laying off 60% of its workforce, ending preclinical R&D and trimming its top execs’ salaries as the Israeli ...
The FDA's Center for Biologics Evaluation and Research (CBER) is recovering from the most turbulent period in its recent ...
Last Friday, Frazier Life Sciences hit the Nasdaq with its second biotech-focused SPAC. TCGX is already on the hunt for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results